Ken, this is a good opportunity to consolidate several threads into one clean reply, so let me do that.
On the AI tinge: the observation is noted. The analytical framework stands on peer-reviewed citations that can be verified independently of whoever compiled them. The conjecture label on forward-looking projections is fair and accepted. What can be documented is documented. What is projected is projected. The two have been kept deliberately separate throughout, though the line between them is not always as clean as it should be.
On credentials: your argument is well-constructed and accepted rather than deflected. Credentials help a reader calibrate the weight of a conjecture, and you are right that the current information environment makes that calibration harder without them. The response to that problem is to keep the analysis anchored to sources the reader can verify independently. Whether that fully resolves the problem you raise is uncertain.
On the ESMO abstract category observation: this is a useful thing. A small correction on the timeline: the ESMO outcome notifications to submitters are expected between July 8 and 10, not July 17. The July 17 date is when accepted abstract titles appear publicly in the program section. Dr. Kasi's team at City of Hope will know the presentation tier approximately one week before the community sees the title. Presidential Symposium means clinical practice-changing. Proffered Paper means original data of superior quality. Rapid Oral means good quality. Poster means acceptable but not oral-worthy.
The ASCO situation is the correct baseline: the CLOVER abstract received no formal presentation slot in January 2026, only an abstract publication. The data available for the ESMO Madrid submission is substantially more mature. The tier assigned between July 8 and 10 will be the first external signal of how the ESMO Scientific Committee weighted it, before a single result number is publicly disclosed. You identified a genuine leading indicator.
Now to Jake's friend, relayed through you via the dunce section of the classroom, which continues to ask better questions than most of the honor roll.
Does size count? Yes, and the published data supports it with more precision than the question implies.
The seven-year HIV leronlimab study published in PLOS Pathogens confirms that both 350mg and 700mg achieved full CCR5 receptor occupancy on peripheral blood CD4+ T cells and monocytes in human participants. In peripheral blood, 350mg is not a subtherapeutic dose. It fully saturates the receptors it can reach in circulation.
The problem is not the blood. It is the liver.
The liver in a colorectal cancer patient with hepatic metastases contains an enormous reservoir of CCR5-bearing cells: Kupffer cells, hepatic stellate cells, recruited monocyte-derived macrophages, CAMLs, tumor-infiltrating myeloid cells, and the CCR5-positive tumor cells themselves in the metastatic lesions. This is the liver sink, and its size is directly proportional to the patient's body mass, liver volume, and metastatic tumor burden. A smaller patient with lower body weight, smaller liver volume, and lower metastatic burden has a proportionally smaller liver sink. The 350mg dose achieves functional CCR5 saturation of that smaller sink more completely than it does in a larger patient whose hepatic CCR5 burden is proportionally greater.
The JCO pooled mTNBC analysis confirms the dose-response signal in oncology specifically: patients treated with 525 to 700mg doses had greater than 75 percent improved median PFS compared to patients at lower doses. That improvement is not simply a pharmacokinetic artifact of larger patients needing more drug. It reflects the biological reality that deeper and more sustained CCR5 saturation in the hepatic and tumor compartments produces more durable immune architecture conversion and more sustained chemotherapy sensitization.
Now add the CCR5 clustering and endocytosis mechanism confirmed in the AACR B019 abstract, where higher leronlimab doses were specifically associated with the formation of CCR5 dots in CAMLs and CTCs. The clustering mechanism means each leronlimab binding event triggers a cascade that removes multiple receptors from the cell surface simultaneously through clathrin-mediated endocytosis, achieving higher functional receptor occupancy than the dose-to-receptor ratio calculation alone suggests. In a smaller patient where the 350mg dose is already approaching saturation of the total receptor burden, the clustering mechanism pushes functional saturation beyond what the arithmetic predicts. In a larger patient with a greater hepatic CCR5 burden, the 700mg dose is required to initiate enough clustering events to achieve the same functional coverage.
This is likely why three of the four complete ctDNA clearances in CLOVER came from the 350mg cohort. Those three patients were probably smaller in body size and lower in hepatic metastatic burden, meaning 350mg achieved functional receptor saturation in their specific liver sink through the clustering mechanism. The fourth complete clearance, from the 700mg cohort, came from a patient whose receptor burden required the higher dose to achieve the same functional saturation.
Jake's friend found a real variable. It is not the whole story, but it is a genuine and published piece of the receptor occupancy architecture.
Size, liver metastatic burden, and the clustering-induced functional saturation mechanism all operate simultaneously, and together they explain why the dose-response question in CLOVER is more nuanced than a simple 350mg versus 700mg comparison implies.
The dunce section keeps finding the right questions. The honor roll potentially could learn something.
On the AI tinge: the observation is noted. The analytical framework stands on peer-reviewed citations that can be verified independently of whoever compiled them. The conjecture label on forward-looking projections is fair and accepted. What can be documented is documented. What is projected is projected. The two have been kept deliberately separate throughout, though the line between them is not always as clean as it should be.
On credentials: your argument is well-constructed and accepted rather than deflected. Credentials help a reader calibrate the weight of a conjecture, and you are right that the current information environment makes that calibration harder without them. The response to that problem is to keep the analysis anchored to sources the reader can verify independently. Whether that fully resolves the problem you raise is uncertain.
On the ESMO abstract category observation: this is a useful thing. A small correction on the timeline: the ESMO outcome notifications to submitters are expected between July 8 and 10, not July 17. The July 17 date is when accepted abstract titles appear publicly in the program section. Dr. Kasi's team at City of Hope will know the presentation tier approximately one week before the community sees the title. Presidential Symposium means clinical practice-changing. Proffered Paper means original data of superior quality. Rapid Oral means good quality. Poster means acceptable but not oral-worthy.
The ASCO situation is the correct baseline: the CLOVER abstract received no formal presentation slot in January 2026, only an abstract publication. The data available for the ESMO Madrid submission is substantially more mature. The tier assigned between July 8 and 10 will be the first external signal of how the ESMO Scientific Committee weighted it, before a single result number is publicly disclosed. You identified a genuine leading indicator.
Now to Jake's friend, relayed through you via the dunce section of the classroom, which continues to ask better questions than most of the honor roll.
Does size count? Yes, and the published data supports it with more precision than the question implies.
The seven-year HIV leronlimab study published in PLOS Pathogens confirms that both 350mg and 700mg achieved full CCR5 receptor occupancy on peripheral blood CD4+ T cells and monocytes in human participants. In peripheral blood, 350mg is not a subtherapeutic dose. It fully saturates the receptors it can reach in circulation.
The problem is not the blood. It is the liver.
The liver in a colorectal cancer patient with hepatic metastases contains an enormous reservoir of CCR5-bearing cells: Kupffer cells, hepatic stellate cells, recruited monocyte-derived macrophages, CAMLs, tumor-infiltrating myeloid cells, and the CCR5-positive tumor cells themselves in the metastatic lesions. This is the liver sink, and its size is directly proportional to the patient's body mass, liver volume, and metastatic tumor burden. A smaller patient with lower body weight, smaller liver volume, and lower metastatic burden has a proportionally smaller liver sink. The 350mg dose achieves functional CCR5 saturation of that smaller sink more completely than it does in a larger patient whose hepatic CCR5 burden is proportionally greater.
The JCO pooled mTNBC analysis confirms the dose-response signal in oncology specifically: patients treated with 525 to 700mg doses had greater than 75 percent improved median PFS compared to patients at lower doses. That improvement is not simply a pharmacokinetic artifact of larger patients needing more drug. It reflects the biological reality that deeper and more sustained CCR5 saturation in the hepatic and tumor compartments produces more durable immune architecture conversion and more sustained chemotherapy sensitization.
Now add the CCR5 clustering and endocytosis mechanism confirmed in the AACR B019 abstract, where higher leronlimab doses were specifically associated with the formation of CCR5 dots in CAMLs and CTCs. The clustering mechanism means each leronlimab binding event triggers a cascade that removes multiple receptors from the cell surface simultaneously through clathrin-mediated endocytosis, achieving higher functional receptor occupancy than the dose-to-receptor ratio calculation alone suggests. In a smaller patient where the 350mg dose is already approaching saturation of the total receptor burden, the clustering mechanism pushes functional saturation beyond what the arithmetic predicts. In a larger patient with a greater hepatic CCR5 burden, the 700mg dose is required to initiate enough clustering events to achieve the same functional coverage.
This is likely why three of the four complete ctDNA clearances in CLOVER came from the 350mg cohort. Those three patients were probably smaller in body size and lower in hepatic metastatic burden, meaning 350mg achieved functional receptor saturation in their specific liver sink through the clustering mechanism. The fourth complete clearance, from the 700mg cohort, came from a patient whose receptor burden required the higher dose to achieve the same functional saturation.
Jake's friend found a real variable. It is not the whole story, but it is a genuine and published piece of the receptor occupancy architecture.
Size, liver metastatic burden, and the clustering-induced functional saturation mechanism all operate simultaneously, and together they explain why the dose-response question in CLOVER is more nuanced than a simple 350mg versus 700mg comparison implies.
The dunce section keeps finding the right questions. The honor roll potentially could learn something.
4
